SCHEMBL5880264

SCHEMBL5880264

O=C(N/N=C/c1ccccc1OS(=O)(=O)c1ccc(C(F)(F)F)cc1)c1ccccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.54
MAPT P10636 8/20 0.49
HTT P42858 7/20 0.49
KMT2A Q03164 6/20 0.49
MEN1 O00255 4/20 0.49
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 4/20 0.47
POLB P06746 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 3/20 0.45
EYA2 O00167 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
PTBP1 P26599 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880267 1.00 LMNA (0.54) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5879930 0.91 LMNA (0.51) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5879920 0.91 RAB9A (0.57) LMNAMAPTHTTKMT2AMEN1
SCHEMBL6375817 0.91 LMNA (0.51) LMNAMAPTHTTKMT2AMEN1
SCHEMBL6438879 0.91 RAB9A (0.57) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5880130 0.89 MAPT (0.50) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5879953 0.89 KMT2A (0.50) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5880133 0.89 MAPT (0.50) LMNAMAPTHTTKMT2AMEN1
SCHEMBL5879956 0.89 KMT2A (0.50) LMNAMAPTHTTKMT2AMEN1
SCHEMBL6379352 0.88 LMNA (0.57) LMNAMAPTHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 LMNA 4281/4885MAPT 4629/4885HTT 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.